Anavex Life Sciences (AVXL) Tax Provisions (2016 - 2025)
Anavex Life Sciences (AVXL) posted Tax Provisions of $18000.0 for Q4 2025, up 126.87% sequentially from -$67000.0 in Q2 2024.
Anavex Life Sciences (AVXL) Tax Provisions (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported Tax Provisions for 10 years, with the latest figure at $18000.0 in Q4 2025.
- Quarterly Tax Provisions changed N/A year-over-year to $18000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $141000.0 (changed N/A YoY) and the FY2023 annual result came in at $7000.0, down 98.04% from the prior year.
- Tax Provisions improved to $18000.0 in Q4 2025 per AVXL's latest filing, from -$67000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $209799.0 in Q3 2022 and troughed at -$67000.0 in Q2 2024.
- A 5-year average of $47647.9 and a median of $39000.0 in 2021 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2021 and 2024: Tax Provisions jumped 1553.32% in 2021, then tumbled 263.41% in 2024.
- Over 5 years, Tax Provisions stood at $29980.0 in 2021, then plunged by 166.71% to -$20000.0 in 2022, then jumped by 525.0% to $85000.0 in 2023, then sank by 178.82% to -$67000.0 in 2024, then soared by 126.87% to $18000.0 in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered $18000.0, -$67000.0, and $105000.0 for Q4 2025, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,000.00 |
| Jun 30, 2024 | -67,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Sep 30, 2023 | -64,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | -20,000.00 |
| Sep 30, 2022 | 209,799.00 |
| Jun 30, 2022 | 88,421.00 |
| Mar 31, 2022 | 29,800.00 |
| Dec 31, 2021 | 29,980.00 |
| Sep 30, 2021 | 142,731.00 |
| Jun 30, 2021 | 39,000.00 |
| Mar 31, 2021 | 26,988.00 |
| Dec 31, 2020 | 59,281.00 |
| Sep 30, 2020 | 8,633.00 |
| Jun 30, 2020 | 4,817.00 |
| Dec 31, 2019 | 9,214.00 |
| Sep 30, 2019 | 6,116.00 |